Nivolumab is a monoclonal antibody and a PD-1 inhibitor (programmed death receptor inhibitor) which is prescribed for cancer treatment. The therapeutic efficacy of Bacillus calmette-guerin ...

With this new treatment, scientists believe they found a way to reduce long-term side effects of therapy—including ... The FDA will determine whether nivolumab should be added as standard ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Nivolumab was first evaluated in a phase I ... with 52% of participants achieving a complete response. No grade 3/4 side effects were observed (Westin et al, 2010). Patients with heavily ...

You have pembrolizumab every 6 weeks or nivolumab and ipilimumab every 4 weeks. You have it as a drip into a vein. You have treatment for up to 2 years as long as it is working and the side effects ...

and most severe side effects being adrenal insufficiency. The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.